Listen to the article
New York’s attorney general has ordered a Manhattan hospital to resume gender-transition treatments for transgender youth, citing potential violations of state anti-discrimination laws in the facility’s recent decision to halt such care.
In a letter made public this week, Attorney General Letitia James instructed NYU Langone to immediately restart its Transgender Youth Health Program, which the hospital discontinued last month. James’ office warned that the cessation of services had “jeopardized access to medically necessary healthcare for some of the most vulnerable New Yorkers.”
NYU Langone, one of New York City’s largest hospital systems, announced in January that it would stop providing certain gender-transition treatments for patients under 19 years of age. Hospital spokesman Steve Ritea attributed the decision to “the recent departure of our medical director, coupled with the current regulatory environment,” describing it as a “difficult decision.”
The hospital had already stopped accepting new patients into its transgender youth program last year following President Donald Trump’s executive order titled “Protecting Children from Chemical and Surgical Mutilation,” which seeks to restrict gender-transition treatments for individuals under 19.
Following Trump’s directive, the U.S. Department of Health and Human Services proposed cutting federal Medicaid and Medicare funding to hospitals that provide gender-transition treatments to transgender youth. This proposal has created financial pressure on healthcare institutions across the country, with several others also suspending similar programs.
However, in the February 25 letter signed by Darsana Srinivasan, the attorney general’s health care bureau chief, James’ office emphasized that the federal proposal had not officially changed existing law and did not impact a “medical institution’s existing duties and obligations under New York law.”
“The sudden discontinuation of medically necessary transgender healthcare can have severe, negative health outcomes,” Srinivasan wrote. “Accordingly, the Attorney General is extremely concerned by your institution’s decision to cease the provision of care to this vulnerable, minority population.”
The letter gives NYU Langone until March 11 to demonstrate compliance with the directive, although specific consequences for non-compliance weren’t detailed. James’ office threatened “further action” if the hospital fails to resume offering hormone therapies, puberty blockers, and other treatments to transgender youth.
This clash highlights the growing tension between federal and state approaches to transgender healthcare. While the Trump administration has moved to restrict such treatments for minors, some state officials like James are pushing back, arguing that these services constitute medically necessary care protected by state anti-discrimination laws.
The situation at NYU Langone reflects a broader national trend. Healthcare institutions across the country face difficult decisions as they navigate conflicting federal directives, potential funding threats, and state-level legal requirements regarding transgender healthcare.
Medical associations including the American Academy of Pediatrics and the American Medical Association have generally supported gender-affirming care as appropriate for some youth with gender dysphoria, while opponents argue such treatments may have long-term consequences for minors.
For transgender youth and their families in New York City, the closure of NYU Langone’s program represents a significant reduction in available healthcare options. The attorney general’s intervention underscores the high stakes involved, both for the affected patients and for the broader legal framework governing access to transgender healthcare.
As this situation continues to develop, it may establish important precedents for how similar conflicts between federal policy and state anti-discrimination laws are resolved nationwide.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
9 Comments
Transgender healthcare is a sensitive and evolving area. I’m curious to hear more details about the specific factors behind the hospital’s decision and the AG’s response. There may be valid concerns on both sides.
It’s good the AG is taking action to protect vulnerable patients, but I hope a collaborative solution can be found that addresses the hospital’s operational challenges as well.
This is a complex issue where reasonable people may disagree. I appreciate the AG’s intention to ensure access to care, but also understand the hospital’s need to navigate a changing regulatory landscape.
Hopefully all parties can work constructively to find a way forward that prioritizes the wellbeing of transgender youth without unduly burdening the healthcare provider.
This is a complex and sensitive issue. While I respect the AG’s directive, I hope the hospital can ensure quality care for transgender youth while navigating the regulatory landscape responsibly.
It’s important transgender youth have access to medically necessary care. Balancing patient needs with evolving regulations poses challenges, but the priority should be supporting vulnerable populations.
Transgender healthcare is an important but contentious topic. I’m curious to learn more about the hospital’s decision and the AG’s response. What factors were considered in each case?
There seem to be valid concerns on both sides. I hope an open dialogue can help find a balanced solution that protects patients while addressing the hospital’s operational challenges.
This is a delicate situation requiring a balanced approach. While I respect the AG’s directive, I hope the hospital and regulators can work together to ensure high-quality care for transgender youth within a sustainable framework.